Floatz logo

Belimumab

Sjogren Syndrome

Peking Union Medical College Hospitalmonoclonal_antibodyPhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Sjogren Syndrome cohort.

Asset / SponsorPhaseRating
Rituximab
Peking Union Medical College Hospital
Phase 4BB
Diluent
Instituto de Oftalmología Fundación Conde de Valenciana
Phase 3B
Bcma-Cd19 Ccar T Cells
Peking University People's Hospital
Phase 2CCC
Car-Nk Cell
Bangdong Gong
Phase 1/2CCC
Daxdilimab
Amgen
Phase 1CC

View all 11 →

Same molecule, other indications

Belimumab is also rated in:

childhood acute lymphoblastic leukemiaActive
B
Indicative · Phase 4
61 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
multiple sclerosisActive
CCC
Indicative · Phase 2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →